公司简介_Qingzhou Xinkang Biotechnology Development Co., Ltd.

Qingzhou Xinkang Biotechnology Development Co., Ltd.

Qingzhou Xinkang Biotechnology Development Co., Ltd. was established in 2011 and is located in the Economic Development Zone of Qingzhou City, Shandong Province, with a factory area covering 5,000 square meters. It is a technology-driven supplier of biopharmaceutical raw materials that integrates research and development of biological extracts, large-scale manufacturing, and domestic and international sales.

We specialize in the research, development, and manufacturing of biopharmaceutical raw materials derived from human urine, including Urokinase (UK), Ulinastatin (UTI), Human chorionic gonadotropin (HCG), Human menopausal gonadotropin (HMG), Follicle-stimulating hormone (FSH), and Luteinizing hormone (LH), with capabilities to supply crudes, intermediates, and APIs.

Xinkang Biotech is committed to providing global customers with the highest-quality products and services, fostering health and enhancing quality of life.

Staff

office

m²

Floor area

production line

million

output value

partner

Corporate Culture

Corporate Vision

vision

Becoming a benchmark for global recycling of biological resources. Let every drop of life resource shine with regenerative value.

Corporate Vision

Becoming a benchmark for global recycling of biological resources. Let every drop of life resource shine with regenerative value.

Corporate Mission

mission

Committed to innovating biotechnology to transform life resources and provide universal solutions for human health.

Corporate Mission

Committed to innovating biotechnology to transform life resources and provide universal solutions for human health.

core values

values

Regeneration/Ethics/Advancement/Innovation/Respect/Loyalty/Responsibility

core values

Regeneration/Ethics/Advancement
Innovation/Respect/Loyalty/Responsibility

Corporate Purpose

Purpose

Sincerity is the foundation, science is the basis, and every trust that safeguards the source of life.

Corporate Purpose

Sincerity is the foundation, science is the basis, and every trust that safeguards the source of life.

Witness the growth and progress of Xinkang together

2011

A team of 3 people has been established, focusing on the production of urokinase and ustertine

2012

Successfully incorporated chorionic gonadotropin (HCG) into the product system

2013

Self built factory opens a new chapter in large-scale production and operation

2014

Launch human menopausal gonadotropin (HMG) and complete the comprehensive layout of core urinary source products (urokinase, ustestatin, HCG, HMG)

2015

Formally registered and established Qingzhou Xinkang Biotechnology Co., Ltd

2016

Business network coverage throughout Weifang

School pipeline upgrade, collection and efficiency improvement

Cooperate with German pharmaceutical companies to establish intermediate purification workshops

2017

Ranked among the 2017 Top 100 Innovative Abilities in China

2018

Significant breakthrough in transportation methods, innovation in on-site adsorption technology; Starting from the Yantai market, we will carry out a province wide layout

2019

Zhengzhou, Anyang, Xuchang, and Nanyang in Henan Province, as new strategic hubs, have begun to outline their nationwide layout

2020

Upgrading of raw material strategy: Successfully expanding pregnant women's urine and elderly women's urine (covering Qingzhou, Linqu, Zibo and other places), enhancing supply chain resilience;

The team has grown to 70 people and the annual revenue has exceeded 50 million

2021

Actively preparing for the construction of a new factory, simultaneously forming a professional R&D team and high standard laboratory, vigorously introducing high-end talents in the industry, injecting core power into future technological innovation and product upgrades

2022

Brand Renewal: The company name has been officially changed to "Qingzhou Xinkang Biotechnology Development Co., Ltd."

2023

Starting from the development of the Shenyang market, we have officially entered Northeast China and taken a crucial step towards a nationwide strategic layout

2024

Leapfrog development;

In May, the overall relocation will be to the Modern Economic Development Zone;

In June, a high standard GMP workshop was completed.

The company has successfully expanded its business to various provinces across the country, completed a nationwide marketing and service network layout, and opened a new era of development

2025

The team has exceeded 110 people, and the independent research and development center has been completed